ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v18i4.2299ppharm-2051Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWНовые данные по эволюции пандемии COVID-19: обзор литературыNew Evidence on the Evolution of the COVID-19 Pandemic: Literature Reviewhttps://orcid.org/0000-0002-2209-7531Намазова-БарановаЛ. С.Namazova-BaranovaLeyla S.

Намазова-БарановаЛейла Сеймуровна - доктор медицинских наук, профессор, академик Российской академии наук.

119333, Москва, ул. Фотиевой, д. 10; телефон: +7 (499) 400-47-33; eLibrary SPIN: 1312-2147

MD, PhD, Professor, Academician of the RAS.

10 Fotievoy Str., 119333 Moscow; +7 (499) 400-47-33; eLibrary SPIN: 1312-2147

info@pediatr-russia.ruhttps://orcid.org/0000-0003-0801-2789СадекиН.М.Я.SadeqiNilab

Садеки НилабМохаммад Ясин - врач-педиатр НИИ охраны и здоровья детей ЦКБ РАН.

119333, Москва, ул. Фотиевой, д 10, стр. 1, тел.: +7 (915) 141-01-94

MD

10/1 Fotievoy Str., 119333 Moscow; +7 (499) 400-47-33

nili42@msn.comhttps://orcid.org/0000-0003-0317-2425ЭфендиеваК. Е.EfendievaKamilla E.

Эфендиева Камилла Евгеньевна - кандидат медицинских наук.

119333, Москва, ул. Фотиевой, д. 10, +7 (499) 400-47-33; eLibrary SPIN: 5773-3901

119333, Москва, ул. Фотиевой, д. 10, +7 (499) 400-47-33; eLibrary SPIN: 5773-3901

kamillaef@inbox.ruРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова; НИИ педиатрии и охраны здоровья детей ЦКБ РАН Министерства науки и высшего образования РФ; Белгородский государственный национальный исследовательский университетРоссияPirogov Russian National Research Medical University; Research Institute of Pediatrics and Children's Health in Central Clinical Hospital of the Russian Academy of Sciences; Belgorod National Research UniversityRussian FederationБелгородский государственный национальный исследовательский университетРоссияResearch Institute of Pediatrics and Children's Health in Central Clinical Hospital of the Russian Academy of SciencesRussian FederationРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова; НИИ педиатрии и охраны здоровья детей ЦКБ РАН Министерства науки и высшего образования РФРоссияPirogov Russian National Research Medical University; Research Institute of Pediatrics and Children's Health in Central Clinical Hospital of the Russian Academy of SciencesRussian Federation202117102021184314319Copyright © Намазова-Баранова Л.С., Садеки Н., Эфендиева К.Е., 20212021Намазова-Баранова Л.С., Садеки Н., Эфендиева К.Е.Namazova-Baranova L.S., Sadeqi N., Efendieva K.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2051

В данной обзорной статье представлены находящиеся в открытом доступе новые сведения об эволюции пандемии COVID-19, вызванной вирусом SARS-CoV-2, в том числе относящиеся к варианту «дельта». Также в статье проанализированы вопросы терминологии и классификации вариантов вируса, выделенных на данный момент, вопросы эффективности вакцинации и использования моноклональных антител против вируса SARS-CoV-2 в отношении нового варианта «дельта». Авторы всех проанализированных материалов на текущий момент считают линию «дельта» вариантом, вызывающим обеспокоенность. Отмечено, что, согласно некоторым публикациям, имеются сведения, указывающие на его повышенную трансмиссивность, более высокий риск госпитализации, возможно, более высокую тяжесть течения заболевания, низкую эффективность применяемых вакцин после частичной вакцинации (например, одна доза для вакцины). Также в статье рассмотрены вопросы, которые касаются возвращения детей, перенесших COVID-19, к занятиям спортом.

This review presents new publicly available data on the evolution of COVID-19 pandemic caused by SARS-CoV-2, as well as on the Delta variant. The article also covers the issues of terminology and classification of already identified virus variants, vaccination efficacy, and the use monoclonal antibodies for SARS-CoV-2 virus and new Delta variant management. The authors of all analyzed publications consider the Delta variant as the most concerning in the present situation. It is noted, there is data (according to some publications) indicating its higher transmissibility, hospitalization risk, likely more severe disease course, low efficacy of vaccines after partial vaccination (e.g. one dose of vaccine). The article also considers issues related to children returning to sport activities after COVID-19.

SARS-CoV-2вариант «дельта»вакцинацияпедиатрияновая коронавирусная инфекцияSARS-CoV-2Delta variantvaccinationpediatricsnew coronavirus infectionНе указанNot specifiedReferencesWHO. Tracking SARS-CoV-2 variants. World Health Organization. August 13, 2021. Available online: https://www.who.int/en/activi-ties/tracking-SARS-CoV-2-variants. Accessed on August 19, 2021.WHO. Tracking SARS-CoV-2 variants. World Health Organization. August 13, 2021. Available online: https://www.who.int/en/activi-ties/tracking-SARS-CoV-2-variants. Accessed on August 19, 2021.Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill. 2021;26(24):2100509. doi: 10.2807/1560-7917.ES.2021.26.24.2100509Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill. 2021;26(24):2100509. doi: 10.2807/1560-7917.ES.2021.26.24.2100509Nasreen S, Chung H, He S, et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv. July 16, 2021. doi: 10.1101/2021.06.28.21259420.Nasreen S, Chung H, He S, et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv. July 16, 2021. doi: 10.1101/2021.06.28.21259420.Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276-280. doi: 10.1038/s41586-021-03777-9Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276-280. doi: 10.1038/s41586-021-03777-9Starr T, Greaney A, Dingens A, et al. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med. April 20, 2021. doi: 10.1016/j.xcrm.2021.100255Starr T, Greaney A, Dingens A, et al. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med. April 20, 2021. doi: 10.1016/j.xcrm.2021.100255AAP. COVID-19 Interim Guidance: Return to Sports and Physical Activity. American Academy of Pediatrics. August 02, 2021. Available online: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/covid-19-interim-guidance-return-to-sports. Accessed on August 19, 2021.AAP. COVID-19 Interim Guidance: Return to Sports and Physical Activity. American Academy of Pediatrics. August 02, 2021. Available online: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/covid-19-interim-guidance-return-to-sports. Accessed on August 19, 2021.Elliott N, Martin R, Heron N, et al. Infographic. Graduated return to play guidance following COVID-19 infection. Br J Sports Med. 2020;54(19):1174-1175. doi: 10.1136/bjsports-2020-102637Elliott N, Martin R, Heron N, et al. Infographic. Graduated return to play guidance following COVID-19 infection. Br J Sports Med. 2020;54(19):1174-1175. doi: 10.1136/bjsports-2020-102637European Centre for Disease Prevention and Control. Threat Assessment Brief: Emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA. Stockholm: ECDC; 2021. Available online: https://www.ecdc.europa.eu/en/publications-data/threat-assessment-emergence-sars-cov-2-b1617-variants. Accessed on August 19, 2021.European Centre for Disease Prevention and Control. Threat Assessment Brief: Emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA. Stockholm: ECDC; 2021. Available online: https://www.ecdc.europa.eu/en/publications-data/threat-assessment-emergence-sars-cov-2-b1617-variants. Accessed on August 19, 2021.WHO. Weekly epidemiological update on COVID-19 — 22 June 2021. Edition 45. World Health Organization. June 22,2021. Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-june-2021. Accessed on August 19, 2021.WHO. Weekly epidemiological update on COVID-19 — 22 June 2021. Edition 45. World Health Organization. June 22,2021. Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-june-2021. Accessed on August 19, 2021.Kuhn JH, Bao Y, Bavari S, et al. Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol. 2012;158(1):301-311. doi: 10.1007/s00705-012-1454-0Kuhn JH, Bao Y, Bavari S, et al. Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol. 2012;158(1):301-311. doi: 10.1007/s00705-012-1454-0CDC. Interim: Implications of the Emerging SARS-CoV-2 Variant VOC 202012/01. Centers for Disease Control and Prevention. December 29, 2020. Available online: https://web.archive.org/web/20210122060907/https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-emerging-variant.html. Accessed on August 19, 2021.CDC. Interim: Implications of the Emerging SARS-CoV-2 Variant VOC 202012/01. Centers for Disease Control and Prevention. December 29, 2020. Available online: https://web.archive.org/web/20210122060907/https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-emerging-variant.html. Accessed on August 19, 2021.Lucey DR. COVID “Mega-variant” and eight criteria for a template to assess all variants. Science Speaks: Global ID News. February 20, 2021. Available online: https://sciencespeaksblog.org/2021/02/02/covid-mega-variant-and-eight-criteria-for-a-template-to-assess-all-variants. Accessed on August 19, 2021.Lucey DR. COVID “Mega-variant” and eight criteria for a template to assess all variants. Science Speaks: Global ID News. February 20, 2021. Available online: https://sciencespeaksblog.org/2021/02/02/covid-mega-variant-and-eight-criteria-for-a-template-to-assess-all-variants. Accessed on August 19, 2021.CDC. Emerging SARS-CoV-2 Variants. Centers for Disease Control and Prevention. January 4, 2021. Available online: https://web.archive.org/web/20210122062629/https://www.cdc.gov/coronavirus/2019ncov/more/science-and-research/scientific-brief-emerging-variants.html. Accessed on August 19, 2021.CDC. Emerging SARS-CoV-2 Variants. Centers for Disease Control and Prevention. January 4, 2021. Available online: https://web.archive.org/web/20210122062629/https://www.cdc.gov/coronavirus/2019ncov/more/science-and-research/scientific-brief-emerging-variants.html. Accessed on August 19, 2021.CDC. SARS-CoV-2 Variant Classifications and Definitions. Centers for Disease Control and Prevention. August 17, 2021. Available online: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html. Accessed on August 19, 2021.CDC. SARS-CoV-2 Variant Classifications and Definitions. Centers for Disease Control and Prevention. August 17, 2021. Available online: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html. Accessed on August 19, 2021.Schematic comparison ofthe GISAID, Next strain and cov-lineages. org nomenclatures for SARS-CoV-2 sequences of world-wide origin, February-July 2020. Eurosurveillance. Available online: https://www.eurosurveillance.org/content/figure/10.2807/1560-7917.ES.2020.25.32.2001410.f1. Accessed on August 19, 2021.Schematic comparison ofthe GISAID, Next strain and cov-lineages. org nomenclatures for SARS-CoV-2 sequences of world-wide origin, February-July 2020. Eurosurveillance. Available online: https://www.eurosurveillance.org/content/figure/10.2807/1560-7917.ES.2020.25.32.2001410.f1. Accessed on August 19, 2021.WHO. Weekly epidemiological update on COVID-19 — 15 June 2021. Edition 44. World Health Organization. June 15, 2021. Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---15-june-2021. Accessed on August 19, 2021.WHO. Weekly epidemiological update on COVID-19 — 15 June 2021. Edition 44. World Health Organization. June 15, 2021. Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---15-june-2021. Accessed on August 19, 2021.Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to global health. Glob Chall. 2017;1(1):33-46. doi: 10.1002/gch2.1018Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to global health. Glob Chall. 2017;1(1):33-46. doi: 10.1002/gch2.1018The Luxembourg Government. COVID-19 cases — Weekly review: 7-13 June. June 16, 2021. Available online: https://covid19.public.lu/en/news-covid19/communiques/2021/06/16-weekly-review.html. Accessed on August 19, 2021.The Luxembourg Government. COVID-19 cases — Weekly review: 7-13 June. June 16, 2021. Available online: https://covid19.public.lu/en/news-covid19/communiques/2021/06/16-weekly-review.html. Accessed on August 19, 2021.Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 16. London: PHE; 2021. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach-ment_data/file/994839/Variants_of_Concern_VOC_Technical_Briefing_16.pdf. Accessed on August 19, 2021.Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 16. London: PHE; 2021. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach-ment_data/file/994839/Variants_of_Concern_VOC_Technical_Briefing_16.pdf. Accessed on August 19, 2021.Reuters. Kremlin blames vaccine hesitancy as Delta variant drives Moscow surge. Reuters. June 18, 2021. Available online: https://www.reuters.com/world/europe/covid-19-cases-hit-an-all-time-daily-high-moscow-2021-06-18. Accessed on August 19, 2021.Reuters. Kremlin blames vaccine hesitancy as Delta variant drives Moscow surge. Reuters. June 18, 2021. Available online: https://www.reuters.com/world/europe/covid-19-cases-hit-an-all-time-daily-high-moscow-2021-06-18. Accessed on August 19, 2021.PANGO lineages. Lineage B.1.617.2. Available online: https://cov-lineages.org/lineages/lineage_B.1.617.2.html. Accessed on August 19, 2021.PANGO lineages. Lineage B.1.617.2. Available online: https://cov-lineages.org/lineages/lineage_B.1.617.2.html. Accessed on August 19, 2021.Scientific Advisory Group for Emergencies. SPI-M-O: Consensus statement on COVID-19, 3 June 2021. Gov.uk. June 14, 2021. Available online: https://www.gov.uk/government/publications/spi-m-o-consensus-statement-on-covid-19-3-june-2021. Accessed on August 19, 2021.Scientific Advisory Group for Emergencies. SPI-M-O: Consensus statement on COVID-19, 3 June 2021. Gov.uk. June 14, 2021. Available online: https://www.gov.uk/government/publications/spi-m-o-consensus-statement-on-covid-19-3-june-2021. Accessed on August 19, 2021.Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 15. London: PHE; 2021. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/993879/Variants_of_Concern_VOC_Technical_Briefing_15.pdf. Accessed on August 19, 2021.Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 15. London: PHE; 2021. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/993879/Variants_of_Concern_VOC_Technical_Briefing_15.pdf. Accessed on August 19, 2021.Stowe J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. Khub [Preprint]. 2021. Available online: https://khub.net/documents/135939561/479607266/Effectiveness+of+COVID19+vaccines+against+hospital+admission+with+the+Delta+%28B.1.617.2%29+variant.pdf/1c213463-3997-ed16-2a6f-14e5deb0b997?t=1623689315431. Accessed on August 19, 2021.Stowe J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. Khub [Preprint]. 2021. Available online: https://khub.net/documents/135939561/479607266/Effectiveness+of+COVID19+vaccines+against+hospital+admission+with+the+Delta+%28B.1.617.2%29+variant.pdf/1c213463-3997-ed16-2a6f-14e5deb0b997?t=1623689315431. Accessed on August 19, 2021.Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461-2462. doi: 10.1016/S0140-6736(21)01358-1Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461-2462. doi: 10.1016/S0140-6736(21)01358-1AAR Children and COVID-19: State-Level Data Report. American Academy of Pediatrics. August 16, 2021. Available online: https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infec-tions/children-and-covid-19-state-level-data-report. Accessed on August 19, 2021.AAR Children and COVID-19: State-Level Data Report. American Academy of Pediatrics. August 16, 2021. Available online: https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infec-tions/children-and-covid-19-state-level-data-report. Accessed on August 19, 2021.U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic. [Updated 2021]. Available online: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use. Accessed on June 13, 2021.U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic. [Updated 2021]. Available online: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use. Accessed on June 13, 2021.European Centre for Disease Prevention and Control. Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA. [Updated 2021]. Available online: https://www.ecdc.europa.eu/en/publications-data/interim-public-health-considerations-covid-19-vaccination-adolescents-eueea. Accessed on June 13, 2021.European Centre for Disease Prevention and Control. Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA. [Updated 2021]. Available online: https://www.ecdc.europa.eu/en/publications-data/interim-public-health-considerations-covid-19-vaccination-adolescents-eueea. Accessed on June 13, 2021.European Medicines Agency. COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU. Available online: https://www.ema.europa.eu/en/news/covid-19-vaccine-spikevax-approved-children-aged-12-17-eu. Accessed on August 28, 2021.European Medicines Agency. COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU. Available online: https://www.ema.europa.eu/en/news/covid-19-vaccine-spikevax-approved-children-aged-12-17-eu. Accessed on August 28, 2021.U.S. National Library of Medicine. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/results?term=vaccine&cond=covid&recrs=a&recrs=d&age_v=&age=0&gndr=&type=&rslt=&Search=Apply. Accessed on August 28, 2021.U.S. National Library of Medicine. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/results?term=vaccine&cond=covid&recrs=a&recrs=d&age_v=&age=0&gndr=&type=&rslt=&Search=Apply. Accessed on August 28, 2021.Fact sheet for health care providers. emergency use authorization (EUA) of REGEN-COV™ (casirivimab and imdevimab). Available online: https://www.fda.gov/media/145611/download. Accessed on August 3, 2021.Fact sheet for health care providers. emergency use authorization (EUA) of REGEN-COV™ (casirivimab and imdevimab). Available online: https://www.fda.gov/media/145611/download. Accessed on August 3, 2021.

The authors declare that there are no conflicts of interest present.